Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Bio Farma SARS-CoV-2 Vaccine in Healthy Adults
NCT05313035Phase 3Completed
- Sponsor
- Bio Farma
- Start
- Apr 2022
- Primary completion
- Jul 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of IndoVac in coronavirus disease 2019 (COVID-19), sponsored by Bio Farma. Started Apr 2022; status: completed.
02
Drugs
IndoVac
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05313035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05313035.